Lucentis Vial

Lucentis vial contains ranibizumab, a monoclonal antibody fragment used to manage retinal diseases like wet AMD, DME, and macular edema following retinal vein occlusion (RVO). It targets VEGF to reduce fluid leakage and neovascularization.

Benefits:

• Enhances or preserves vision
• Decreases retinal swelling and bleeding
• Flexible dosing schedule based on clinical response
• Used in various vision-threatening retinal disorders

Dosage:

• 0.5 mg (0.05 mL) intravitreal injection monthly
• After the initial phase, you may switch to less frequent dosing
• Administered under sterile clinical conditions

Warnings and Precautions:

• Monitor for infection or increased intraocular pressure
• Avoid active ocular infections
• Requires sterile handling and preparation
• Must be administered by trained professionals only

Usage Instructions:

• The vial should be used with a sterile syringe and filter needle
• Prepare and administer according to clinical protocols
• Post-injection eye monitoring is necessary
• Educate patients on symptoms of infection

Storage Information:

• Store at 2–8°C
• Do not freeze
• Keep it in the original carton to protect it from light
• Use immediately after preparation

Common Side Effects:

• Eye irritation or redness
• Floaters
• Inflammation inside the eye
• Risk of infection